Real-World Outcomes in Patients with EGFR/ALK-Positive NSCLC Treated with Chemotherapy Following 1 or 2 Lines of TKI Therapy

被引：0
|
作者：
Cheema, P. [1 ]
Ton, T. [2 ]
Lambert, P. [2 ]
Merritt, D. [3 ]
Morris, S. [3 ]
Shankar, G. [2 ]
Ganti, A. K. [4 ,5 ]
机构：
[1] Univ Toronto, William Osler Hlth Syst, Toronto, ON, Canada
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA
[5] Univ Nebraska Med Ctr, Omaha, NE USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TT01.01
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [41] Clinical Outcomes of Crizotinib in Real-World Practice Settings for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer
    Davis, K. L.
    Lenz, C.
    Houghton, K.
    Kaye, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 238 - 239
  • [42] Real-World Clinical Outcomes of Crizotinib Treatment in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases
    Davis, K. L.
    Lenz, C.
    Houghton, K.
    Kaye, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 239 - 239
  • [43] ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario
    Singh, Ajaykumar
    Kapoor, Akhil
    Noronha, Vanita
    Patil, Vijay
    Menon, Nandini
    Mahajan, Abhishek
    Janu, Amit
    Purandare, Nilendru
    Kaushal, Rajiv
    Prabhash, Kumar
    ECANCERMEDICALSCIENCE, 2022, 16
  • [44] Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
    Li, Jia
    Han, Baohui
    Liu, Huaimin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Real-world clinical outcomes in Chinese patients with EGFR-mutated NSCLC progressed from first-line EGFR-TKI: A prospective multicenter study
    Tian, Panwen
    Wu, Lin
    Zhou, Chengzhi
    Tan, Jie
    Wang, Ke
    Luo, Feng
    Liu, Yongmei
    Guo, Yubiao
    Li, Yinyin
    Liu, Zhe
    Gong, Youling
    Wang, Yongsheng
    Li, Weimin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Real-World Treatment Patterns and Outcomes in ALK plus NSCLC Patients Receiving Immuno-Oncology Therapy in the United States
    Pan, X.
    Lin, H.
    Yin, Y.
    Cheng, M.
    Baumann, P.
    Jahanzeb, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S883 - S883
  • [47] Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles
    Riely, G.
    Lovly, C.
    Messina, C.
    Bienert, S.
    Alexander, K.
    Pao, W.
    Magee, K.
    Baxi, S.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S365 - S366
  • [48] Real-World Characteristics and Outcomes of Advanced NSCLC Patients with Exon 19 or 21 EGFR Mutations
    Winfree, K.
    Molife, C.
    Peterson, P.
    Chen, Y.
    Visseren, C.
    Beyrer, J.
    Leusch, M.
    Dimou, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S23 - S23
  • [49] Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
    Ou, Sai-Hong Ignatius
    Lin, Huamao Mark
    Hong, Jin-Liern
    Yin, Yu
    Jin, Shu
    Lin, Jianchang
    Mehta, Minal
    Nguyen, Danny
    Neal, Joel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Real-world gastric cancer patients treated with at least three lines of chemotherapy: Outcomes and predictors for efficacy.
    Valentina, Fanotto
    Mario, Uccello
    Irene, Pecora
    Lorenza, Rimassa
    Francesco, Leone
    Gerardo, Rosati
    Daniele, Santini
    Riccardo, Giampieri
    Samantha, Di Donato
    Gianluca, Tomasello
    Nicola, SIlvestris
    Filippo, Pietrantonio
    Francesca, Battaglin
    Antonio, Avallone
    Mario, Scartozzi
    Stefania, Lutrino
    Davide, Melisi
    Lorenzo, Antonuzzo
    Antonio, Pellegrino
    Giuseppe, Aprile
    ANNALS OF ONCOLOGY, 2017, 28
12345